NEEDHAM, Mass.--(BUSINESS WIRE)--March 9, 2006--AVANT Immunotherapeutics (Nasdaq: AVAN) today announced that the company has received a $4 million milestone payment from GlaxoSmithKline (GSK). This payment marks the approval from the European Commission for Rotarix(R) in the European Union (EU). Rotarix(R) will be the first rotavirus vaccine available to children in Europe for the prevention of gastroenteritis caused by rotavirus.
